Rescue of Immunotherapy-Refractory Metastatic Merkel Cell Carcinoma With Conventionally Fractionated Radiotherapy and Concurrent Pembrolizumab

Merkel cell carcinoma has historically had dismal prognosis with limited cytotoxic chemotherapy options that provide durable control of metastatic disease. The advent of anti-programmed death protein (anti-PD1)/anti-programmed death-ligand 1 (anti-PD-L1) directed immunotherapy has shown initial prom...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Front Oncol
Autores principales: Bloom, Brooke C., Augustyn, Alexander, Pezzi, Todd A., Menon, Hari, Mayo, Lauren L., Shah, Shalin J., Schwartz, David L., Chmura, Steven J., Johnson, Faye M., Welsh, James W., Chun, Stephen G.
Formato: Artigo
Lenguaje:Inglês
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6459944/
https://ncbi.nlm.nih.gov/pubmed/31024834
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00223
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares